At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,010 enrolled
Drug / intervention
Inhaled corticosteroid +1 moredrug
Likely dose
Inhaled corticosteroid 500mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Acute Respiratory Infections and Asthma in U-5 Children: Improved Treatment to Reduce Morbidity and Mortality in Uganda, A Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Inhaled corticosteroid and Placebo for Bacterial Pneumonia and 2 related conditions. Completed, enrolled 1,010 participants across 1 site.
Detailed Summary
The purpose of this study is to find out whether adjunct treatment with inhaled corticosteroids lead to faster improvement and reduce mortality of children under 5 years of age admitted to hospital with ALRI.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Pneumonia, Viral Pneumonia, Acute Asthma
CountriesUganda
CollaboratorsUniversity of Copenhagen
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedJun 2013
Primary CompletionJan 2014
TodayJul 2026
First PostedJun 4, 2013
Enrollment StartDec 1, 2012
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.1 years ago
Interventions
Inhaled corticosteroiddrug
Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
Placeboother
Placebo to be administered 12hourly